{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:53:22Z","timestamp":1787316802468,"version":"build-2736575974"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tirabrutinib is a potent, irreversible, and highly selective Bruton\u2019s tyrosine kinase (BTK) inhibitor that has demonstrated significant therapeutic activity in patients with relapsed or refractory B-cell lymphoma. However, the safety and efficacy of tirabrutinib monotherapy have not been systematically assessed. This meta-analysis aims to assess the safety and efficacy of tirabrutinib monotherapy in patients with B-cell lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a comprehensive literature search in Embase, PubMed, Web of Science, and Cochrane Library databases to identify prospective clinical trials evaluating tirabrutinib monotherapy in B-cell lymphoma. Data on efficacy and safety were extracted and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of seven studies were included in the meta-analysis. The clinical trials primarily involved patients with chronic lymphocytic leukemia (CLL), primary central nervous system lymphoma (PCNSL), mantle cell lymphoma (MCL), and Waldenstr\u00f6m\u2019s macroglobulinemia (WM). The pooled overall response rate (ORR) was 72.5%, with complete response (CR) rate of 18.6%, stable disease (SD) rate of 13.8%, and partial response (PR) rate of 41.1%. The highest median progression-free survival (mPFS) was observed in patients with CLL, reaching 38.5 months. Neutropenia was the most common adverse event (AE), both all grades and grade \u22653. Additionally, a high incidence of skin-related AEs was reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tirabrutinib monotherapy demonstrates a manageable safety profile and promising efficacy in patients with B-cell lymphoma. However, these findings need to be confirmed by larger and higher-quality randomized controlled trials in the future. Further research should also explore the long-term effects and potential benefits of combination therapies involving tirabrutinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>Identifier CRD42024552721.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1559056","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T02:12:24Z","timestamp":1743473544000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of tirabrutinib monotherapy in relapsed or refractory B-cell lymphomas\/leukemia: a meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Jingfei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-en","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunke","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guimao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1756-8722-6-59","article-title":"Ibrutinib and novel BTK inhibitors in clinical development","volume":"6","author":"Akinleye","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11899-019-00512-0","article-title":"Targeting BTK in CLL: beyond ibrutinib","volume":"14","author":"Bond","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0211228","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PLoS One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1016\/s2352-3026(20)30224-6","article-title":"Consensus treatment recommendations from the tenth international workshop for Waldenstr\u00f6m macroglobulinaemia","volume":"7","author":"Castillo","year":"2020","journal-title":"Lancet Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1158\/1078-0432.Ccr-19-3504","article-title":"Phase ib study of tirabrutinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia","volume":"26","author":"Danilov","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.2174\/0109298673251030231004052822","article-title":"Pirtobrutinib: first non-covalent tyrosine kinase inhibitor for treating relapsed or refractory mantle cell lymphoma in adults","volume":"31","author":"De","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-025-01513-y","article-title":"From development to clinical success: the journey of established and next-generation BTK inhibitors","author":"Gupta","year":"2025","journal-title":"Invest. New Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40360-024-00832-9","article-title":"Real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies","volume":"26","author":"Karimi","year":"2025","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"6685","DOI":"10.1182\/blood-2022-156472","article-title":"Real-World evidence for the safety and effectiveness of tirabrutinib in 140 Japanese patients with recurrent or refractory primary central nervous system lymphoma: interim report of postmarketing surveillance","volume":"140","author":"Kawasaki","year":"2022","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/14712598.2020.1822318","article-title":"Anti-CD20 treatment for B-cell malignancies: current status and future directions","volume":"21","author":"Klein","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0282166","DOI":"10.1371\/journal.pone.0282166","article-title":"Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics","volume":"18","author":"Kozaki","year":"2023","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e729","DOI":"10.1097\/hs9.0000000000000729","article-title":"Efficacy and safety of tirabrutinib and idelalisib with or without obinutuzumab in relapsed chronic lymphocytic leukemia","volume":"6","author":"Kutsch","year":"2022","journal-title":"Hemasphere"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s11912-023-01476-4","article-title":"Integrative approaches in the treatment of patients affected by lymphoma","volume":"25","author":"Levy","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"129531","DOI":"10.1016\/j.bbagen.2020.129531","article-title":"Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition","volume":"1864","author":"Liclican","year":"2020","journal-title":"Biochim. Biophys. Acta-Gen Subj."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0290872","DOI":"10.1371\/journal.pone.0290872","article-title":"Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib","volume":"18","author":"Lin","year":"2023","journal-title":"PLoS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1007\/s10238-023-01208-9","article-title":"Evaluation of Bruton tyrosine kinase inhibitors monotherapy and combination therapy in lymphocytic leukemia","volume":"23","author":"Liu","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-021-01134-x","article-title":"Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1080\/14740338.2020.1802424","article-title":"Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma","volume":"19","author":"Makita","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/cas.13983","article-title":"Phase I study of tirabrutinib (ONO-4059\/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan","volume":"110","author":"Munakata","year":"2019","journal-title":"Cancer Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s12185-022-03514-6","article-title":"Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies","volume":"117","author":"Munakata","year":"2023","journal-title":"Int. J. Hematol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/oncolo\/oyac260","article-title":"Managing ibrutinib-intolerant patients with B-cell malignancies","volume":"28","author":"Mu\u00f1oz","year":"2023","journal-title":"Oncologist"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1182\/blood-2024-202096","article-title":"Cardiac safety profiles of first-generation vs. Second-generation BTK inhibitors: a meta-analysis","volume":"144","author":"Mushtaq","year":"2024","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita","year":"2021","journal-title":"Neuro Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40164-021-00222-5","article-title":"Histological verification of the treatment effect of tirabrutinib for relapsed\/refractory primary central nervous system lymphoma","volume":"10","author":"Okita","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1120009x.2024.2357980","article-title":"Meta-analysis of the efficacy and adverse effects of acalabrutinib in the management of relapsed\/refractory chronic lymphocytic leukemia","author":"Park","year":"2024","journal-title":"J. Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"103238","DOI":"10.1016\/j.critrevonc.2021.103238","article-title":"Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: a systematic review and meta-analysis","volume":"159","author":"Pellegrini","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40199-022-00444-w","article-title":"Efficacy and safety of ibrutinib in mantle cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Roufarshbaf","year":"2022","journal-title":"Daru"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/s41375-019-0658-7","article-title":"Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS\/ONO-4059)","volume":"34","author":"Rule","year":"2020","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1080\/10428194.2024.2333985","article-title":"Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances","volume":"65","author":"Schaff","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1111\/cas.15344","article-title":"Two-year outcomes of tirabrutinib monotherapy in Waldenstr\u00f6m's macroglobulinemia","volume":"113","author":"Sekiguchi","year":"2022","journal-title":"Cancer Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B34","doi-asserted-by":"publisher","first-page":"106286","DOI":"10.1016\/j.leukres.2019.106286","article-title":"Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma","volume":"88","author":"Tanaka","year":"2020","journal-title":"Leukemia Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s42358-024-00401-y","article-title":"Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments","volume":"64","author":"Tavakoli","year":"2024","journal-title":"Adv. Rheumatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1182\/blood-2017-02-765115","article-title":"Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO\/GS-4059","volume":"129","author":"Walter","year":"2017","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/hon.2933","article-title":"The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma","volume":"39","author":"Wang","year":"2021","journal-title":"Hematol. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1070660","DOI":"10.3389\/fimmu.2022.1070660","article-title":"Safety and efficacy of dual PI3K-\u03b4, \u03b3 inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: a systematic review and meta-analysis of prospective clinical trials","volume":"13","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","article-title":"Second-generation inhibitors of Bruton tyrosine kinase","volume":"9","author":"Wu","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00277-023-05486-x","article-title":"Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia\/small lymphocytic lymphoma: a systematic review and meta-analysis","volume":"103","author":"Yin","year":"2024","journal-title":"Ann. Hematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s11912-023-01476-4","article-title":"Integrative approaches in the treatment of patients affected by lymphoma","volume":"25","author":"Yurkovski","year":"2023","journal-title":"Curr. Oncol. Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1559056\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T02:12:25Z","timestamp":1743473545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1559056\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":42,"alternative-id":["10.3389\/fphar.2025.1559056"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1559056","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"article-number":"1559056"}}